EG 427 Raises €27M to Advance Genetic Medicine Pipeline
Deal News | Feb 20, 2025 | Andera Partners
EG 427, a biotechnology firm specializing in genetic medicines for chronic neurological diseases, has secured €27 million in a Series B financing round. The round was co-led by Andera Partners and Bpifrance, with participation from the SCI Ventures fund and existing investors. This funding is intended to finance the Phase 1b/2a study of EG 427’s lead product, EG110A, targeting neurogenic detrusor overactivity in spinal cord injury patients. The financial support will also expand EG 427's pipeline through its proprietary HERMES vector technology. MTS Health Partners acted as the exclusive financial advisor for this transaction.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- France – Andera Partners and Bpifrance, the main investors in the funding round, are based in France.
- United States – The clinical trials for EG110A are being conducted in the US, marking it a significant geography for the company's operations.
Industry
- Biotechnology – EG 427 operates within the biotechnology sector, focusing on developing genetic medicines for chronic diseases in neurology.
- Healthcare – The funding and development efforts are aimed at addressing significant medical needs in healthcare, particularly concerning neuro-urology pathologies.
- Private Equity – The involvement of investment firms Andera Partners and Bpifrance highlights the role of private equity in funding innovative biotech ventures.
Financials
- €27 million – The total amount raised by EG 427 in the Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EG 427 | Target Company | Company | A biotechnology company developing genetic medicines for chronic neurological diseases. |
| Andera Partners | Co-Lead Investor | Company | A private equity firm based in France specializing in growth investments. |
| Bpifrance | Co-Lead Investor | Company | France's public investment bank that supports businesses through financing and equity investments. |
| SCI Ventures | Investor | Company | A specialist fund backed by major spinal cord injury foundations. |
| MTS Health Partners | Financial Advisor | Company | An investment bank that acted as the exclusive financial advisor in the financing round. |
| Philippe Chambon | CEO | Person | Chief Executive Officer of EG 427, overseeing the company's strategic direction and clinical advancements. |
| Benot Barteau | Investment Director | Person | Investment Director at Bpifrance overseeing the InnoBio funds. |
| Raphal Wisniewski | Partner | Person | Partner at Andera Partners involved in the investment in EG 427. |